We therefore evaluated the growth and viability of sarcoma cells in the presence of verteporfin (0.125–2 μmol/L), an FDA-approved second-generation photosensitizer for the treatment of age-related macular degeneration that inhibits YAP1/TAZ signaling by suppression of the YAP1/TAZ-TEAD transcription complex and augmenting YAP1 sequestration in the cytoplasm15–19. Here, WWTR1 is linked to age-related macular degeneration.